|
AU2017203312A1
|
|
Methods And Compositions For Disrupting Biofilm Utilizing Chitosan-Derivative Compounds
|
|
CA3017975A1
|
|
Compositions and methods of their use
|
|
WO2017030981A1
|
|
Polymers and their methods of use
|
|
AU2015255317A1
|
|
Methods and Compositions for Disrupting Biofilm Utilizing Chitosan-Derivative Compounds
|
|
EP3190886A1
|
|
Compositions and methods of use thereof
|
|
AU2015200865A1
|
|
Chitosan-Derivative Compounds and Methods of Controlling Microbial Populations
|
|
AU2014254388A1
|
|
Compositions and methods of use for wound healing
|
|
WO2014165226A2
|
|
Oral formulation of polyglucosamine derivatives in combination with a non-fermentable sugar
|
|
AU2013317871A1
|
|
Methods for treatment or prevention of damage resulting from radiation, trauma or shock
|
|
AU2013211460A1
|
|
Chitosan-Derivative Compounds and Methods of Controlling Microbial Populations
|
|
US2015031610A1
|
|
Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
|
|
AU2011237682A1
|
|
Methods and compositions for treating wounds utilizing chitosan compounds
|
|
CA2806559A1
|
|
Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
|
|
EP2473043A1
|
|
Oral care methods and compositions utilizing chitosan-derivative compounds
|
|
CA2751268A1
|
|
Nucleic acid delivery using modified chitosans
|
|
AU2009313937A1
|
|
Chitosan derivatives alone or in combination for the treatment of MDR microbial infections
|
|
CA2743624A1
|
|
Chitosan derivatives to treat animals or optimize animal health
|
|
WO2010021930A1
|
|
Prevention and treatment of mrsa infections with chitosan-derivatives
|
|
EP3144324A1
|
|
Chitosan-derivative compounds and methods of controlling microbial populations
|
